QIA.DE

The company maintains a strong liquidity position, with a current ratio of 3.9, indicating a robust ability to meet short-term obligations. However, the company has a net cash position that is negative after subtracting total debt, which could pose a liquidity risk in the medium term. The debt-to-equity ratio of 0.44 suggests a relatively conservative capital structure, with a balance between debt and equity financing. Profitability metrics show a return on equity of 11.25% and a return on assets of 6.76%, which are key indicators of the company's efficiency in generating returns for shareholders and asset utilization. These figures are in line with the industry's preferred metrics, suggesting the company is performing at a level consistent with its peers. The company's revenue is primarily derived from its operations in the healthcare diagnostics industry, with no specific geographic concentration disclosed. The lack of detailed segment or geographic breakdown limits the ability to assess potential risks from over-reliance on specific markets or product lines. Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue forecasted for the current and next fiscal years. This stability is supported by consistent operating cash flow and a manageable capital expenditure profile. The company faces a medium liquidity risk, primarily due to its net cash position being negative after subtracting total debt. While the dilution risk is currently low, any future capital raising activities could affect the ownership structure. The company has not disclosed any recent dilutive events, and the dilution potential remains minimal. Recent events and filings do not indicate any major operational or financial disruptions. The company's financial health appears stable, with no significant red flags in the latest disclosures. Analysts have provided a range of price targets, with a mean of 44.82 USD and a median of 44.20 USD, reflecting a generally positive outlook.